B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice.
about
Cloning and characterization of a cellular apoptosis susceptibility gene, the human homologue to the yeast chromosome segregation gene CSE1The human CAS protein which is homologous to the CSE1 yeast chromosome segregation gene product is associated with microtubules and mitotic spindlePseudomonas exotoxin antisense RNA selectively kills hepatitis B virus infected cellsTARP: a nuclear protein expressed in prostate and breast cancer cells derived from an alternate reading frame of the T cell receptor gamma chain locusBispecific digoxigenin-binding antibodies for targeted payload deliveryImproving antibody affinity by mimicking somatic hypermutation in vitro.Specific killing of HIV-infected lymphocytes by a recombinant immunotoxin directed against the HIV-1 envelope glycoproteinIsolation of new anti-CD30 scFvs from DNA-immunized mice by phage display and biologic activity of recombinant immunotoxins produced by fusion with truncated pseudomonas exotoxin.Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity.Protein engineering of antibodies.Trends in immunoconjugate and ligand-receptor based targeting development for cancer therapy.A novel composite immunotoxin that suppresses rabies virus production by the infected cells.Isolation and characterization of pokeweed antiviral protein mutations in Saccharomyces cerevisiae: identification of residues important for toxicityImmunotoxins.Recombinant immunotoxins for cancer therapy.Intrathecal administration of single-chain immunotoxin, LMB-7 [B3(Fv)-PE38], produces cures of carcinomatous meningitis in a rat modelPrimate antibody response to immunotoxin: serological and computer-aided analysis of epitopes on a truncated form of Pseudomonas exotoxin.Random recombination of antibody single chain Fv sequences after fragmentation with DNaseI in the presence of Mn2+.Disulfide-stabilized single-chain antibody-targeted superantigen: construction of a prokaryotic expression system and its functional analysis.Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotoxImmunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components.Rapid humanization of the Fv of monoclonal antibody B3 by using framework exchange of the recombinant immunotoxin B3(Fv)-PE38.A recombinant immunotoxin that is active on prostate cancer cells and that is composed of the Fv region of monoclonal antibody PR1 and a truncated form of Pseudomonas exotoxin.In vitro and in vivo antitumor effects of the recombinant immunotoxin IL6(T23)-PE38KDEL in multiple myelomaPeptide-specific killing of antigen-presenting cells by a recombinant antibody-toxin fusion protein targeted to major histocompatibility complex/peptide class I complexes with T cell receptor-like specificity.Expression cloning of cDNAs that render cancer cells resistant to Pseudomonas and diphtheria toxin and immunotoxins.A recombinant immunotoxin containing a disulfide-stabilized Fv fragment.A novel vascular endothelial growth factor-directed therapy that selectively activates cytotoxic prodrugs.Fungal ribotoxins: molecular dissection of a family of natural killers.Medical applications of single-chain antibodies.An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes.Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: targeting with a single chain antibody variable domain isolated by phage display.Independent domain folding of Pseudomonas exotoxin and single-chain immunotoxins: influence of interdomain connectionsRecombinant anti-erbB2 immunotoxins containing Pseudomonas exotoxinTargeting TARP, a novel breast and prostate tumor-associated antigen, with T cell receptor-like human recombinant antibodies.Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity.An update in the use of antibodies to treat glioblastoma multiforme.Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity.Human toxin-based recombinant immunotoxins/chimeric proteins as a drug delivery system for targeted treatment of human diseases.Targeted toxins in brain tumor therapy.
P2860
Q24303588-F3B3D745-C7D5-4458-97A1-3F93548D1D6BQ24568254-95285E1C-8CB9-49BE-AABA-05A9B3DA518CQ24648726-143B3CB3-11D2-4145-90BD-3B698CD2C694Q24673353-FE4E3361-BB4A-4716-9225-D2E3F31785DEQ27667652-00708BE6-2218-47E0-922A-D6C7BE81416CQ30724948-0E2F2736-60EF-4759-AF35-FBBFC6BA8AD9Q30862548-939B323B-BAFF-4EDC-AC5A-188198B2EF51Q31915221-CE66C645-3983-459B-A2BB-772BDB612159Q32140773-560ACD42-082B-4037-8C55-5CA4676B508FQ33192279-96A00E81-1801-4B1F-9609-9A2B1F8AACF8Q33311571-A16D3804-F04E-4458-804D-C76C506FC81CQ33665168-75C471DF-61D1-4528-91C0-1CFAA78E3759Q33981471-C789370E-0F20-436E-AC2C-2D0EB2917C3FQ34181903-F54EBC87-0238-43B1-B9B1-E81ABF8C1929Q34451921-68DBAA15-24C0-4D8D-A7A8-162906E6F2ADQ34500814-F94CEDAF-6E47-4AB1-8AEE-47FC8153FB68Q34545123-4B8A3807-6DC3-461C-8056-582D75453B04Q34765967-E25A4175-9043-431E-8845-29F7A2CD4424Q35435876-20B48141-BE75-4799-AC1A-EEEA4AC3CFE7Q35446035-3D3D9604-A652-4D7A-8312-1CE0C8E15257Q35459059-BFEA39CD-609D-4CB5-9A8D-7E26ED41F793Q35956476-0FE32777-3E9F-4FBC-9BE3-27C39B9AC5A8Q36060020-96D8B623-8C9A-462E-B79A-19B3DE5A3D7CQ36110386-3C09A177-FC7D-4579-86EE-B2F176643FDBQ36142259-FBB617C4-B334-4753-AD34-91D5C1210F5CQ36437495-72E293DF-8035-4ABC-91C7-45FC3AD38C4DQ36476431-6BBF64CB-DBA3-4968-BF02-DAC93761F2B2Q36648881-A13E8E64-9CB4-4853-A2DC-880E78A889ACQ36718512-0D9CE604-518B-45A6-B851-CD4F9DB9E463Q36767989-513F2B09-25B9-4B68-A9B7-D6DE08FD8C51Q36837402-A841326A-2CF3-41CD-88B8-DD644E4F6975Q36837485-53C30823-2A1B-49A1-ADD4-C428840495D9Q36936476-450EDC2B-D802-4775-8E3D-DFDA1840FD46Q37082263-E62FFD40-8483-4862-ADDA-456DB98AAC23Q37192915-CFD8EF9E-1C36-481A-8258-2DCEDE2BE329Q37232738-2B846332-1AB8-4742-B602-9EC9703BA14BQ37329927-67CD2CB9-806C-4EF7-BC56-4A64CE8D26D9Q37342848-D914BEFF-2810-479E-9175-73B88B738400Q37859775-88992C90-007C-4844-B047-03363C9ECB91Q37954275-3F58F897-1280-4B2E-A97D-2B04C278702D
P2860
B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 1991
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
B3(Fv)-PE38KDEL, a single-chai ...... of a human carcinoma in mice.
@en
B3(Fv)-PE38KDEL, a single-chai ...... of a human carcinoma in mice.
@nl
type
label
B3(Fv)-PE38KDEL, a single-chai ...... of a human carcinoma in mice.
@en
B3(Fv)-PE38KDEL, a single-chai ...... of a human carcinoma in mice.
@nl
prefLabel
B3(Fv)-PE38KDEL, a single-chai ...... of a human carcinoma in mice.
@en
B3(Fv)-PE38KDEL, a single-chai ...... of a human carcinoma in mice.
@nl
P2093
P2860
P356
P1476
B3(Fv)-PE38KDEL, a single-chai ...... of a human carcinoma in mice.
@en
P2093
Brinkmann U
FitzGerald DJ
Willingham M
P2860
P304
P356
10.1073/PNAS.88.19.8616
P407
P577
1991-10-01T00:00:00Z